Seeking Alpha

RDEA
Ardea Biosciences, Inc.

5/26/2012, 10:19 AM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
RDEA Market Currents more »
  • April 23 AstraZeneca's (AZN -1.8%) purchase of Ardea Biosciences (RDEA +51.5%) may be the first in a series of deals for the company. The drug developer is considering buying other late-stage assets outside its research and development focus on cancer, diabetes and gastrointestinal ailments, in an effort to counter looming generic competition.
    Comment!
    [Healthcare, M&A, On the Move]
RDEA in Focus more »
RDEA News more »
RDEA Latest Transcript more »
Currently, there are no transcripts for RDEA.
RDEA Cramer more »
Currently, there are no Cramer articles on RDEA.
RDEA Instablog posts more »
  • A Dozen Stockdiagnostics' Upgrades Recently Acquired
    Thu, May 3 • Thomas Renna • 1 Comment
  • Barchart Morning Call 3/12
    Mon, Mar 12 • Jim Van Meerten • Comment!
  • Ardea Biosciences scores 100% response rate in trials for gout drug
    Mon, Nov 8, 2010 • Proactive Investor • Comment!
  • Daily Updates at AndrewNava.com (Focus on ADLR, BPAX, CRIS)
    Mon, Jun 21, 2010 • Andrew Nava • Comment!
  • Three Biotech Trades for EULAR (IMMU, RDEA, TRBN)
    Tue, Jun 8, 2010 • Andrew Nava • Comment!
Write a post on RDEA
RDEA StockTalks
RDEA vs. ETF Alternatives
Company Description
Currently, there's no company description for RDEA.